Fennec Pharmaceuticals Inc (FENC) Smart Money Holdings (13F, Q2 2026)

FENC ranks #4416 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

FENC is a top-conviction position for Rosalind Advisors, Inc. — at 12.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

AIGH Capital Management LLC has added to its FENC position for two straight quarters, increasing it by $14.5M to reach $26.7M today.

Ken Griffin has trimmed its FENC position for two straight quarters, cutting it by $774.5K while still holding $763.6K.

FENC is up 2.3% today, and institutions have been net buyers of $33.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

FENC reported a net loss of $3.3M over the trailing twelve months.

• Not yet profitable — net loss of $3.3M over the trailing twelve months
• Revenue grew 77.8% year over year
• Net income improved year over year, from -$12.0M to -$3.3M
• Operating cash flow was negative, using $12.5M in cash
• Current ratio of 6.37x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.99x equity — within a conventional range